News for Avicanna Inc. (AVCN.TO)

In a significant achievement for Avicanna (AVCNF), the company has announced its first profitable quarter, marking a crucial milestone in its business developme

**media[626861]**

Revenue: $25.5 million, a 52% increase from the previous year.Gross Profit: $12.9 million, representing a 51% gross margin, up from 40% in 2023.Net Loss: Reduc

Apr 22, 2025 / 12:30PM GMTAras Azadian - Avicanna Inc - Chief Executive Officer, Director So good morning, everyone. Thank you for joining our 2024 earnings and

Avicanna Inc. (AVCNF) has announced that the Ontario Securities Commission (OSC) has lifted the Management Cease Trade Order (MCTO) that was imposed on April 4.

**media[596681]**

2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023 TORONTO, April 14, 2025

Avicanna (AVCNF) reports a remarkable 52% increase in revenue, reaching $25.5 million for 2024. The company's gross profit surged by 94% to $12.9 millio

**media[588455]**

Auditor Licensing & Personnel Issues Delays Issuance of Audit Opinion

Bridging Science and Clinical Practice: A Gathering of Thought Leaders in Cannabinoid Medicine

TORONTO, March 21, 2025 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic i…

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced t...

Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada TORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- A

Cosmetic registration and delivery into Germany completed in preparation for the initial commercial Launch

**media[466835,466836]**

TORONTO, Oct. 10, 2024 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic in…

Avicanna Inc. (OTC: AVCNF) biopharmaceutical company announced Thursday the successful export of its Aureus-branded cannabigerol (CBG) products to Denmark.

Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023